-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, REGENXBIO Presents Three-Year Sura-Vec Data Showing Majority Of NPDR Participants Achieved Greater Than 2-Step DRSS Improvement, No Vision-Threatening Events

Benzinga·09/25/2026 07:18:22
Listen to the news
  • Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy
  • No IOI observed with short-course prophylactic topical steroids